A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Clinical trial NCT03075527 · TERMINATED
Trial details
- NCT number
- NCT03075527
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-04-10
- Primary completion
- 2019-06-07
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.